Genetically Modified DR5-Specific TRAIL Variant DR5-B Revealed Dual Antitumor and Protumoral Effect in Colon Cancer Xenografts and an Improved Pharmacokinetic Profile

Despite the weak clinical efficacy of TRAIL death receptor agonists, a search is under way for new agents that more efficiently activate apoptotic signaling. We previously created a TRAIL DR5-selective variant DR5-B without affinity for the DR4, DcR1, DcR2, and OPG receptors and increased proapoptot...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Transl Oncol
Prif Awduron: Yagolovich, Anne V., Artykov, Artem A., Karmakova, Tatiana A., Vorontsova, Maria S., Pankratov, Andrey A., Andreev-Andrievsky, Alexander A., Dolgikh, Dmitry A., Kirpichnikov, Mikhail P., Gasparian, Marine E.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Neoplasia Press 2020
Pynciau:
Original article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7110358/
https://ncbi.nlm.nih.gov/pubmed/32224450
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.tranon.2020.100762
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg